GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Equity-to-Asset

Molecular Partners AG (XSWX:MOLN) Equity-to-Asset : 0.89 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Molecular Partners AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was CHF176.43 Mil. Molecular Partners AG's Total Assets for the quarter that ended in Dec. 2023 was CHF198.35 Mil. Therefore, Molecular Partners AG's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.89.

The historical rank and industry rank for Molecular Partners AG's Equity-to-Asset or its related term are showing as below:

XSWX:MOLN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.52   Med: 0.72   Max: 0.9
Current: 0.89

During the past 11 years, the highest Equity to Asset Ratio of Molecular Partners AG was 0.90. The lowest was 0.52. And the median was 0.72.

XSWX:MOLN's Equity-to-Asset is ranked better than
84.11% of 1567 companies
in the Biotechnology industry
Industry Median: 0.66 vs XSWX:MOLN: 0.89

Molecular Partners AG Equity-to-Asset Historical Data

The historical data trend for Molecular Partners AG's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Equity-to-Asset Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 0.57 0.62 0.90 0.89

Molecular Partners AG Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.91 0.89 0.90 0.89

Competitive Comparison of Molecular Partners AG's Equity-to-Asset

For the Biotechnology subindustry, Molecular Partners AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Equity-to-Asset falls into.



Molecular Partners AG Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Molecular Partners AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=176.429/198.352
=0.89

Molecular Partners AG's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=176.429/198.352
=0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Molecular Partners AG  (XSWX:MOLN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Molecular Partners AG Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG (XSWX:MOLN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG (XSWX:MOLN) Headlines

From GuruFocus